WALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other ... announced today multiple oral and poster presentations at the American Association for Cancer ...

Quanta is progressing three, chemically distinct, oral KRAS inhibitors targeting the most common mutations in KRAS. QTX3034 is an allosteric multi-KRAS inhibitor with G12D-preferring activity.